

Target-MRD™

Redefining Precision With Dual Insight

Tumor-Informed + Tumor-Agnostic
Molecular Residual Disease
Monitoring



Monitor in
Real Time



Personalize
Treatment



Assess Therapy
Outcomes



Detect Relapse
Early

DATAR
CANCER GENETICS

DUAL LAYERED PROFILING



- Target-MRD™ is the only minimal residual disease (MRD) detection assay to implement personalized **tumor-informed cum tumor-agnostic** MRD detection and profiling.
- Profiling tumor-specific variants through personalized assay development is customized to identify patient specific mutation. This tailored approach enhances the sensitivity and specificity of detecting minimal residual disease (MRD) by targeting predefined, known mutations with a limit of detection (LOD) of 0.01%.
- Tumor-agnostic approach is useful for a broader detection spectrum, and can capture tumor heterogeneity and clonal evolution that may be missed in a tumor-informed approach.

MRD Challenges Are Complex. Target-MRD™ Can Help.



Early Detection of Relapse

MRD enables the detection of residual cancer cells at the molecular level before clinical or radiological relapse, allowing for earlier intervention and potentially better outcomes.



Tailored Treatment Decisions

MRD status informs personalized treatment decisions, helping clinicians decide whether to escalate, de-escalate, or discontinue treatment, depending on the presence of molecular disease.



Prognostic Indicator

Detecting MRD provides valuable prognostic information, as patients with undetectable MRD often show improved outcomes, while those with detectable MRD are at higher risk of recurrence.



Guide to Post-Treatment Surveillance


MRD detection allows for ongoing monitoring in patients who are in remission, enabling dynamic adjustments of treatment and earlier detection of recurrence than traditional surveillance methods.

Why Target-MRD™?



Robust Sensitivity

Combination of Tumor-informed and Tumor-agnostic MRD assays



Synergy of Technologies

Utilising the two most advanced MRD technologies; NGS and ddPCR for accurate MRD detection



Robust Specificity





Paired gDNA analysis to rule out CHIP

UNDERSTANDING THE DISEASE IS **THE FIRST STEP** TOWARDS DEFEATING IT


Minimal residual disease refers to the small number of cancer cells that can remain in a person's body after treatment, even when tests show no visible signs of cancer. These remaining cells can sometimes lead to a relapse. Molecular Residual Disease testing helps doctors find this residual cancer activity early, which can guide decisions on further treatment. Accurate MRD detection can inform treatment decisions, improve patient outcomes, and provide an early warning of relapse. Target-MRD™ is a personalized diagnostic test that evaluates circulating tumor DNA (ctDNA) to qualitatively assess Molecular Residual Disease (MRD) in patients with a history of solid tumors.

RESULT

MRD testing serves various purposes. For instance, it can identify residual disease earlier than standard methods such as clinical or radiographic assessments.

Result	Post-Surgery	During Follow-up
MRD - Positive (ctDNA Detected)	 Residual Disease	 Recurrence
MRD - Negative (ctDNA Not Detected)	 Complete Molecular Response	 Complete Molecular Response

HOW IS TARGET-MRD™ PERFORMED?



DATAR CANCER GENETICS

Contact us:

✉ : response@datarpgx.com

🌐 datarpgx.com
targetmrd360.com

Accreditations for Our Lab in India

